ReviewThe Journal of infection2023
Redefining Staphylococcus aureus bacteremia: A structured approach guiding diagnostic and therapeutic management.
Review in The Journal of infection, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 56 citations in OpenAlex.
- Methicillin-resistant Staphylococcus aureus.Nature reviews. Disease primers · 2026Review
- Subphenotype- and complication-guided adjunctive fosfomycin versus standard monotherapy inThe Lancet regional health. Europe · 2026Article
- Analysis of Clinical Subphenotypes in Methicillin-ResistantOpen forum infectious diseases · 2025Article
- Bridging the gap in bloodstream infection management: a survey among non-infectious disease physicians.JAC-antimicrobial resistance · 2025Article
- Review
- Clinical characteristics and efficacy of short-course antibiotic therapy forMicrobiology spectrum · 2025Article
- Comparison of Clinical Characteristics and Outcomes Between MRSA and MSSA Infections Among Patients in Intensive Care Units.Microorganisms · 2025Article
- Exploring catalase inhibition as an adjuvant to antimicrobial photodynamic therapy against Staphylococcus aureus.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2025Article
- Identification and validation of clinical phenotypes inEClinicalMedicine · 2025Article
- Interpreting Blood Culture Results as Early Guidance for Infective Endocarditis.JAMA network open · 2025Article
- Clinical revenues of selective use of [18F]-FDG-PET/CT scanning in the management of Staphylococcus aureus bacteremia.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Review
- Association of Daily Body Temperature, White Blood Cell Count, and C-reactive Protein With Mortality and Persistent Bacteremia in Patients WithOpen forum infectious diseases · 2025Article
- Review
- Piezoelectric biosensor with dissipation monitoring enables the analysis of bacterial lytic agent activity.Scientific reports · 2025Article
- Rapid differentiation ofMicrobiology spectrum · 2024Observational
- The role of [18F]FDG-PET/CT in Staphylococcus aureus bacteremia: A clinical perspective.Npj imaging · 2024Review
- Epidemiology and clinical relevance of persistent bacteraemia in patients with Gram-negative bloodstream infection: a retrospective cohort study.The Journal of antimicrobial chemotherapy · 2024Article
- Low-Risk Staphylococcus aureus Bacteremia Patients Do Not Require Routine Diagnostic Imaging: A Multicenter, Retrospective, Cohort Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Impact of a Bundle of Interventions on Quality-of-Care Indicators forAntibiotics (Basel, Switzerland) · 2024Article
Corrections and comments
- Commented on by
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
The current duration of therapy in patients with Staphylococcus aureus bacteremia (SAB) is based on differentiating complicated from uncomplicated disease. While this approach allows clinicians and investigators to group SAB patients into broadly similar clinical categories, it fails to account for the intrinsic heterogeneity of SAB. This is due in part to the fact that risk factors for metastatic infection and confirmed metastatic infection are considered as equivalent in most scoring systems. In this viewpoint, we propose a two-step system of categorizing patients with SAB. Initially, patients with SAB would be categorized as 'high risk' or 'low risk' for metastatic infection based upon an initial set of diagnostic procedures. In the second step, patients identified as 'high-risk' would undergo additional diagnostic evaluation. The results of this stepwise diagnostic evaluation would define a 'final clinical diagnosis' to inform an individualized final treatment plan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.